Closely watched data from Eli Lilly and Viking Therapeutics this month have reignited the discussion around oral weight-loss drugs—and their ultimate place within the anti-obesity medication market.
> Listen on Spotify
> Listen on Apple Products
> Listen on Amazon Music
> Listen on iHeart
Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This month, shares of both Eli Lilly and Viking Therapeutics took a hit as investors reacted negatively to highly anticipated Phase III and Phase II results for their respective candidates.
While the 9.1% placebo-adjusted weight loss generated by Lilly’s orforglipron over 72 weeks was an efficacy miss by most analyst accounts, tolerability tripped up oral VK2735’s otherwise best-case efficacy scenario—10.9% weight loss after just 13 weeks. These murky results have left observers wondering, just how game-changing these pills will be and which ones will be most effective?
In such a hot space, Lilly’s and Viking’s results—which follow Novo Nordisk’s new drug application for an oral form of Wegovy in May—are only the tip of the iceberg. Stay tuned to BioSpace for further in-depth coverage of the space as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland.
More Obesity Coverage
- Oral Obesity Candidates Disappoint With Novo Emerging as Leader of the Pack
- Weight-Loss Wasteland: 5 Obesity Assets That Failedv
- Which Weight Loss Treatments Will Be Most Effective?
- 5 Oral Obesity Drugs Challenging Lilly’s Orforglipron
- Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires
- Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
- Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting
- Analysts Home In on Safety as Novo, Lilly, Amgen Highlight Weight Loss Data at ADA
